王佳丽,高鹏,范静波,程中伟,邓华,程康安,方全

• 1:中国医学科学院北京协和医学院北京协和医院心内科

摘要(Abstract)：

目的分析影响非瓣膜病心房颤动(房颤)卒中高危人群(CHA2DS2-VASc评分≥2分者)启用华法林和坚持服用华法林治疗的因素。方法纳入2011年8月至2015年4月北京协和医院抗凝门诊及住院登记注册的非瓣膜病房颤且CHA2DS2-VASc评分≥2分患者,除外射频消融患者,分为接受华法林治疗的华法林组和未接受华法林治疗的对照组。比较两组患者基本情况,用logistic回归分析影响华法林使用的因素,Kaplan-Meier曲线和Cox回归分析华法林组坚持服药患者的情况及其影响因素。结果共480例患者(华法林组245例,对照组235例)纳入分析,平均随访时间为(40.0±11.5)个月。血栓栓塞史(OR 2.447,95%CI 1.435~4.171,P=0.001)、慢性心力衰竭史(OR2.009,95%CI 1.084~3.724,P=0.027)、持续性房颤(OR 2.231,95%CI 1.448~3.437,P=0.0001)患者华法林使用率高,而贫血(OR 0.479,95%CI 0.238~0.964,P=0.039)、服用中药(OR 0.638,95%CI 0.456~0.891,P=0.008)以及长期就诊医院距离较远(OR 0.759,95%CI 0.610~0.945,P=0.014)患者华法林使用率较低。华法林组随访期间176例(71.8%)坚持服用华法林,Kaplan-Meier曲线中华法林组患者坚持服药率1年为78.3%,3年为71.0%。入组前服用华法林患者中76例(80.0%,76/95)坚持服用华法林,新启用华法林患者中100例(66.7%,100/150)坚持服用华法林,前者坚持服药率明显高于后者(P=0.008)。与华法林停用相关的因素为新启用华法林(HR 1.786,95%CI 1.029~3.100,P=0.039)、服用中药(HR 1.687,95%CI 1.201~2.370,P=0.003)、长期就诊医院距离较远(HR 1.446,95%CI 1.121~1.865,P=0.005)。结论抗凝门诊中,服用中药和长期就诊医院距离较远等因素影响华法林启用和坚持抗凝,明确影响华法林抗凝治疗相关因素有助于提高患者的依从性。

关键词(KeyWords)： 心房颤动;抗凝治疗;华法林

Abstract:

Keywords:

基金项目(Foundation): 基金项目:北京市科委中国人房颤抗凝治疗最佳强度范围的比较效果研究(D11110700300000)

作者(Author): 王佳丽,高鹏,范静波,程中伟,邓华,程康安,方全

参考文献(References)：

• [1]Flegel KM,Shipley MJ,Rose G.Risk of stroke in non-rheumatic atrial fibrillation.Lancet,1987,1(8532):526-529.
• [2]Hart RG,Pearce LA,Aguilar MI.Meta-analysis:antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.Ann Intern Med,2007,146(12):857-867.
• [3]周自强,胡大一,陈捷,等.中国心房颤动现状的流行病学研究.中华内科杂志,2004,43(7):491-494.
• [4]孙艺红,胡大一.非瓣膜病心房颤动患者全球抗凝注册研究中国亚组基线数据分析.中华心血管病杂志,2014,42(10):846-850.
• [5]高鹏,方全,王佳丽,等.非瓣膜病心房颤动患者抗凝不足状况及原因分析.中华心血管病杂志,2013,41(11):931-934.
• [6]Ewen E,Zhang Z,Simon TA,et al.Patterns of warfarin use and subsequent outcomes in atrial fibrillation in primary care practices.Vasc Health Risk Manag,2012,8:587-598.
• [7]European Heart Rhythm Association,European Association for Cardio-Thoracic Surgery,Camm AJ,et al.Guidelines for the management of atrial fibrillation:the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology(ESC).Europace,2010,12(10):1360-1420.
• [8]Bungard TJ,Ghali WA,Teo KK,et al.Why do patients with atrial fibrillation not receive warfarin?Arch Intern Med,2000,160(1):41-46.
• [9]Baczek VL,Chen WT,Kluger J,et al.Predictors of warfarin use in atrial fibrillation in the United States:a systematic review and meta-analysis.BMC Fam Pract,2012,13:5.
• [10]Gallagher AM,Rietbrock S,Plumb J,et al.Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice:do the appropriate patients receive stroke prophylaxis?J Thromb Haemost,2008,6(9):1500-1506.
• [11]Fang MC,Go AS,Chang Y,et al.Warfarin discontinuation after starting warfarin for atrial fibrillation.Circ Cardiovasc Qual Outcomes,2010,3(6):624-631.
• [12]Song X,Sander SD,Varker H,et al.Patterns and predictors of use of warfarin and other common long-term medications in patients with atrial fibrillation.Am J Cardiovasc Drugs,2012,12(4):245-253.
• [13]Spivey CA,Qiao Y,Liu X,et al.Discontinuation/interruption of warfarin therapy in patients with nonvalvular atrial fibrillation.J Manag Care Spec Pharm,2015,21(7):596-606.
• [14]Suh DC,Choi JC,Schein J,et al.Factors associated with warfarin discontinuation,including bleeding patterns,in atrial fibrillation patients.Curr Med Res Opin,2013,29(7):761-771.
• [15]Chua YT,Ang XL,Zhong XM,et al.Interaction between warfarin and Chinese herbal medicines.Singapore Med J,2015,56(1):11-18.
• [16]Niu JW,Yuan J,Gao S,et al.Low awareness of stroke guidelines and preference for Chinese herbs in community physicians:a national survey in China.Ann Transl Med,2014,2(8):76.
• [17]Chan HT,So LT,Li SW,et al.Effect of herbal consumption on time in therapeutic range of warfarin therapy in patients with atrial fibrillation.J Cardiovasc Pharmacol,2011,58(1):87-90.